SRPT

Sarepta Therapeutics, Inc. Press Releases

$13.53
*  
0.17
1.27%
Get SRPT Alerts
*Delayed - data as of Mar. 4, 2015 11:46 ET  -  Find a broker to begin trading SRPT now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
View:    SRPT Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2014 Financial Results and Recent Corporate Developments
2/26/2015 7:00:00 AM - Business Wire


Sarepta Therapeutics to Present Company Overview at Upcoming Conferences
2/24/2015 8:30:00 AM - Business Wire


Liberty Global Partnership Continues TransGaming''s GameTree TV Expansion
2/24/2015 8:30:00 AM - Market Wire


Vector Group to Host Fourth Quarter and Full-Year 2014 Results Conference Call
2/19/2015 8:30:00 AM - Business Wire


Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2014 Financial Results and Corporate Update on February 26, 2015
2/19/2015 8:30:00 AM - Business Wire


Sarepta Therapeutics to Present Company Overview at Upcoming Conferences
2/4/2015 8:30:00 AM - Business Wire


Sarepta Therapeutics Announces First Patient Dosed in European Phase I/II Study of SRP-4053 in Duchenne Muscular Dystrophy Patients
1/14/2015 8:30:00 AM - Business Wire
▲16.64 % Price Change since this news event. The Volume Ratio is 0.53.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Insys Therapeutics to Initiate Five Phase III Clinical Trials in 2015
1/12/2015 7:00:00 AM - Market Wire


Sarepta Therapeutics Reports Long-Term Outcomes through 168 Weeks from Phase IIb Study of Eteplirsen in Duchenne Muscular Dystrophy
1/12/2015 7:00:00 AM - Business Wire
▼-3.36 % Price Change since this news event. The Volume Ratio is 4.06.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Sarepta Therapeutics, Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors
1/7/2015 10:47:00 AM - Business Wire
▼-7.46 % Price Change since this news event. The Volume Ratio is 0.81.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


MEDNAX Announces Acquisition of Anesthesiology Practice in Tennessee
1/5/2015 7:00:00 AM - Business Wire